Craniopharyngioma Treatment with PEGIntron – Phase II

PBTC-039: Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma

Protocol Description

This Pediatric Brain Tumor Research Consortium trial is studying how well peginterferon alfa-2b (PEGIntron) works in treating younger patients with a craniopharyngioma that is recurrent or cannot be removed by surgery. PEGIntron may interfere with the growth of tumor cells and slow the growth of craniopharyngioma.

Study Level: Phase II

Eligibility Criteria

Subject to certain exclusion criteria, this study is open to males and females, ages 18 months to 25 years old, who have craniopharyngioma that is recurrent or cannot be surgically removed.
Males and Females: Ages 18 months to 25 years


Following an initial physical exam, participants will receive PEGIntron via injection at home once a week for each week of a 6-week course. This will be repeated for up to 18 courses. At specific intervals, researchers will require other tests, including blood and urine tests, ophthalmology evaluations and MRI scans of the brain.
Visits: 10
Duration: Approximately 2 years

Status: Open for Enrollment

Source(s) of Support

Pediatric Brain Tumor Consortium (Study PBTC-039)
National Cancer Institute

Primary Investigator

A. Kim Ritchey, MD

Contact Information

For more information about the study or enrollment, please contact:
Research Coordinator Angela Connelly, RN, BSN